Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

Lawrence Einhorn, Mary J. Brames, Robert Dreicer, Craig R. Nichols, Michael T. Cullen, Joseph Bubalo

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Goals of work: The aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus dexamethasone in patients receiving highly emetogenic multiple-day cisplatin-based chemotherapy for germ cell tumors. Materials and methods: Forty-one men undergoing 5-day cisplatin-based chemotherapy for testicular cancer received palonosetron 0.25 mg IV once daily 30 min before chemotherapy on days 1, 3, and 5 plus IV dexamethasone 20 mg before chemotherapy on days 1 and 2, and 8 mg PO bid on days 6 and 7 and 4 mg bid on day 8. Safety and efficacy were assessed in 24-h intervals for 9 days. Efficacy endpoints included emesis, intensity of nausea and its interference with patient functioning, and rescue antiemetic use. A subset of patients (n=11) was studied for electrocardiograph effects and pharmacokinetic evaluation. Main results: This multiple-day antiemetic regimen was safe, with headache and constipation the most common treatment-related adverse events, mostly mild. Neither adverse events nor electrocardiographic changes appeared to increase in frequency, duration, or intensity over time despite a 1.42-fold systemic accumulation of palonosetron with repeated doses. The majority of patients had no emesis at any time throughout days 1-5 (51%) or days 6-9 (83%), had no moderate-to-severe nausea, and did not require rescue medication. Most patients reported that nausea had no significant effect on daily functioning on days 1-4 (72%) and days 5-9 (85%). Conclusions: Palonosetron on days 1, 3, and 5, along with a regimen of dexamethasone, was safe and well tolerated and effectively controlled both nausea and emesis in patients undergoing 5-day cisplatin-based chemotherapy for testicular cancer.

Original languageEnglish
Pages (from-to)1293-1300
Number of pages8
JournalSupportive Care in Cancer
Volume15
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Germ Cell and Embryonal Neoplasms
Nausea
Dexamethasone
Cisplatin
Vomiting
Drug Therapy
Antiemetics
Testicular Neoplasms
Safety
Constipation
Headache
palonosetron
Electrocardiography
Pharmacokinetics

Keywords

  • Chemotherapy-induced nausea and vomiting
  • Cisplatin
  • Multiple-day
  • Palonosetron
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. / Einhorn, Lawrence; Brames, Mary J.; Dreicer, Robert; Nichols, Craig R.; Cullen, Michael T.; Bubalo, Joseph.

In: Supportive Care in Cancer, Vol. 15, No. 11, 11.2007, p. 1293-1300.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Brames, Mary J. ; Dreicer, Robert ; Nichols, Craig R. ; Cullen, Michael T. ; Bubalo, Joseph. / Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. In: Supportive Care in Cancer. 2007 ; Vol. 15, No. 11. pp. 1293-1300.
@article{50d43a3a42b5475a9e956ddf55c80234,
title = "Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer",
abstract = "Goals of work: The aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus dexamethasone in patients receiving highly emetogenic multiple-day cisplatin-based chemotherapy for germ cell tumors. Materials and methods: Forty-one men undergoing 5-day cisplatin-based chemotherapy for testicular cancer received palonosetron 0.25 mg IV once daily 30 min before chemotherapy on days 1, 3, and 5 plus IV dexamethasone 20 mg before chemotherapy on days 1 and 2, and 8 mg PO bid on days 6 and 7 and 4 mg bid on day 8. Safety and efficacy were assessed in 24-h intervals for 9 days. Efficacy endpoints included emesis, intensity of nausea and its interference with patient functioning, and rescue antiemetic use. A subset of patients (n=11) was studied for electrocardiograph effects and pharmacokinetic evaluation. Main results: This multiple-day antiemetic regimen was safe, with headache and constipation the most common treatment-related adverse events, mostly mild. Neither adverse events nor electrocardiographic changes appeared to increase in frequency, duration, or intensity over time despite a 1.42-fold systemic accumulation of palonosetron with repeated doses. The majority of patients had no emesis at any time throughout days 1-5 (51{\%}) or days 6-9 (83{\%}), had no moderate-to-severe nausea, and did not require rescue medication. Most patients reported that nausea had no significant effect on daily functioning on days 1-4 (72{\%}) and days 5-9 (85{\%}). Conclusions: Palonosetron on days 1, 3, and 5, along with a regimen of dexamethasone, was safe and well tolerated and effectively controlled both nausea and emesis in patients undergoing 5-day cisplatin-based chemotherapy for testicular cancer.",
keywords = "Chemotherapy-induced nausea and vomiting, Cisplatin, Multiple-day, Palonosetron, Testicular cancer",
author = "Lawrence Einhorn and Brames, {Mary J.} and Robert Dreicer and Nichols, {Craig R.} and Cullen, {Michael T.} and Joseph Bubalo",
year = "2007",
month = "11",
doi = "10.1007/s00520-007-0255-6",
language = "English",
volume = "15",
pages = "1293--1300",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

AU - Einhorn, Lawrence

AU - Brames, Mary J.

AU - Dreicer, Robert

AU - Nichols, Craig R.

AU - Cullen, Michael T.

AU - Bubalo, Joseph

PY - 2007/11

Y1 - 2007/11

N2 - Goals of work: The aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus dexamethasone in patients receiving highly emetogenic multiple-day cisplatin-based chemotherapy for germ cell tumors. Materials and methods: Forty-one men undergoing 5-day cisplatin-based chemotherapy for testicular cancer received palonosetron 0.25 mg IV once daily 30 min before chemotherapy on days 1, 3, and 5 plus IV dexamethasone 20 mg before chemotherapy on days 1 and 2, and 8 mg PO bid on days 6 and 7 and 4 mg bid on day 8. Safety and efficacy were assessed in 24-h intervals for 9 days. Efficacy endpoints included emesis, intensity of nausea and its interference with patient functioning, and rescue antiemetic use. A subset of patients (n=11) was studied for electrocardiograph effects and pharmacokinetic evaluation. Main results: This multiple-day antiemetic regimen was safe, with headache and constipation the most common treatment-related adverse events, mostly mild. Neither adverse events nor electrocardiographic changes appeared to increase in frequency, duration, or intensity over time despite a 1.42-fold systemic accumulation of palonosetron with repeated doses. The majority of patients had no emesis at any time throughout days 1-5 (51%) or days 6-9 (83%), had no moderate-to-severe nausea, and did not require rescue medication. Most patients reported that nausea had no significant effect on daily functioning on days 1-4 (72%) and days 5-9 (85%). Conclusions: Palonosetron on days 1, 3, and 5, along with a regimen of dexamethasone, was safe and well tolerated and effectively controlled both nausea and emesis in patients undergoing 5-day cisplatin-based chemotherapy for testicular cancer.

AB - Goals of work: The aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus dexamethasone in patients receiving highly emetogenic multiple-day cisplatin-based chemotherapy for germ cell tumors. Materials and methods: Forty-one men undergoing 5-day cisplatin-based chemotherapy for testicular cancer received palonosetron 0.25 mg IV once daily 30 min before chemotherapy on days 1, 3, and 5 plus IV dexamethasone 20 mg before chemotherapy on days 1 and 2, and 8 mg PO bid on days 6 and 7 and 4 mg bid on day 8. Safety and efficacy were assessed in 24-h intervals for 9 days. Efficacy endpoints included emesis, intensity of nausea and its interference with patient functioning, and rescue antiemetic use. A subset of patients (n=11) was studied for electrocardiograph effects and pharmacokinetic evaluation. Main results: This multiple-day antiemetic regimen was safe, with headache and constipation the most common treatment-related adverse events, mostly mild. Neither adverse events nor electrocardiographic changes appeared to increase in frequency, duration, or intensity over time despite a 1.42-fold systemic accumulation of palonosetron with repeated doses. The majority of patients had no emesis at any time throughout days 1-5 (51%) or days 6-9 (83%), had no moderate-to-severe nausea, and did not require rescue medication. Most patients reported that nausea had no significant effect on daily functioning on days 1-4 (72%) and days 5-9 (85%). Conclusions: Palonosetron on days 1, 3, and 5, along with a regimen of dexamethasone, was safe and well tolerated and effectively controlled both nausea and emesis in patients undergoing 5-day cisplatin-based chemotherapy for testicular cancer.

KW - Chemotherapy-induced nausea and vomiting

KW - Cisplatin

KW - Multiple-day

KW - Palonosetron

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=35348818158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348818158&partnerID=8YFLogxK

U2 - 10.1007/s00520-007-0255-6

DO - 10.1007/s00520-007-0255-6

M3 - Article

C2 - 17436025

AN - SCOPUS:35348818158

VL - 15

SP - 1293

EP - 1300

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -